| Literature DB >> 10675273 |
H Kitamura1, A Ohta, M Sekimoto, M Sato, K Iwakabe, M Nakui, T Yahata, H Meng, T Koda, S Nishimura, T Kawano, M Taniguchi, T Nishimura.
Abstract
alpha-Galactosylceramide (alpha-GalCer), a glycolipid antigen, specifically activates natural killer T (NKT) cells by a CD1d-restricted mechanism. In this work, we found that in vivo administration of alpha-GalCer resulted in the activation of B cells in addition to NKT cells, namely, alpha-GalCer administration caused upregulation of the early activation marker, CD69, on both NKT and B cells. In addition, expression of B7.2 and I-A(b) on B cells was greatly upregulated by alpha-GalCer. However, serum levels of IgE, IgG1, and IgG2a were not significantly changed within 48 h. In the present experiments, it was also demonstrated that the upregulation of CD69 expression by alpha-GalCer was strongly blocked by anti-IL-4 monoclonal antibody. Moreover, B-cell activation by alpha-GalCer was not observed in NKT-deficient mice. These results suggested that antigen-stimulated NKT cells might play a critical role not only in early defense mechanisms but also in early B-cell activation through IL-4 production. Copyright 2000 Academic Press.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10675273 DOI: 10.1006/cimm.1999.1602
Source DB: PubMed Journal: Cell Immunol ISSN: 0008-8749 Impact factor: 4.868